Skip to main content
Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
11.96
+0.39 (3.37%)
At close: Aug 13, 2025, 4:00 PM
11.99
+0.03 (0.25%)
After-hours: Aug 13, 2025, 7:48 PM EDT

Roivant Sciences Revenue

Roivant Sciences had revenue of $2.17M in the quarter ending June 30, 2025, a decrease of -72.84%. This brings the company's revenue in the last twelve months to $23.23M, down -81.89% year-over-year. In the fiscal year ending March 31, 2025, Roivant Sciences had annual revenue of $29.05M, down -11.19%.

Revenue (ttm)
$23.23M
Revenue Growth
-81.89%
P/S Ratio
351.35
Revenue / Employee
$30,977
Employees
750
Market Cap
8.16B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Mar 31, 202529.05M-3.66M-11.19%
Mar 31, 202432.71M1.18M3.75%
Mar 31, 202331.53M-23.76M-42.97%
Mar 31, 202255.29M31.49M132.34%
Mar 31, 202123.80M-43.89M-64.85%
Mar 31, 2020 Pro Pro Pro
Mar 31, 2019 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 422.82B
Johnson & Johnson 90.63B
Merck & Co. 63.62B
AbbVie 58.33B
AstraZeneca 56.50B
Novartis AG 55.19B
Eli Lilly and Company 53.26B
Novo Nordisk 49.11B
Revenue Rankings

ROIV News

More News